La maladie de Parkinson au Canada (serveur d'exploration) - Exploration (Accueil)

Index « Mesh.i » - entrée « Drug Therapy, Combination »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Drug Synergism < Drug Therapy, Combination < Drug Tolerance  Facettes :

List of bibliographic references indexed by Drug Therapy, Combination

Number of relevant bibliographic references: 33.
[0-20] [0 - 20][0 - 33][20-32][20-40]
Ident.Authors (with country if any)Title
000450 (2016) Maribel Márquez-Cruz [Mexique] ; Juan Pablo Díaz-Martínez [Canada] ; Herman Soto-Molina [Mexique] ; Adib Jorge De Saráchaga [Mexique] ; Amin Cervantes-Arriaga [Mexique] ; Rodrigo Llorens-Arenas [Mexique] ; Mayela Rodríguez-Violante [Mexique]A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America.
000689 (2015) Clive Ballard [Royaume-Uni] ; Stuart Isaacson [États-Unis] ; Roger Mills [États-Unis] ; Hilde Williams [États-Unis] ; Anne Corbett [Royaume-Uni] ; Bruce Coate [États-Unis] ; Rajesh Pahwa [États-Unis] ; Olivier Rascol [France] ; David J. Burn [Royaume-Uni]Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.
000747 (2015) Karl Kieburtz [États-Unis] ; Barbara C. Tilley ; Jordan J. Elm ; Debra Babcock [États-Unis] ; Robert Hauser [États-Unis] ; G Webster Ross [États-Unis] ; Alicia H. Augustine [États-Unis] ; Erika U. Augustine [États-Unis] ; Michael J. Aminoff [États-Unis] ; Ivan G. Bodis-Wollner ; James Boyd ; Franca Cambi ; Kelvin Chou ; Chadwick W. Christine [États-Unis] ; Michelle Cines [États-Unis] ; Nabila Dahodwala [États-Unis] ; Lorelei Derwent [Canada] ; Richard B. Dewey ; Katherine Hawthorne [États-Unis] ; David J. Houghton [États-Unis] ; Cornelia Kamp [États-Unis] ; Maureen Leehey ; Mark F. Lew [États-Unis] ; Grace S Lin Liang [États-Unis] ; Sheng T. Luo ; Zoltan Mari [États-Unis] ; John C. Morgan ; Sotirios Parashos [États-Unis] ; Adriana Pérez ; Helen Petrovitch [États-Unis] ; Suja Rajan ; Sue Reichwein [États-Unis] ; Jessie Tatsuno Roth [États-Unis] ; Jay S. Schneider [États-Unis] ; Kathleen M. Shannon [États-Unis] ; David K. Simon [États-Unis] ; Tanya Simuni [États-Unis] ; Carlos Singer [États-Unis] ; Lewis Sudarsky [États-Unis] ; Caroline M. Tanner [États-Unis] ; Chizoba C. Umeh [États-Unis] ; Karen Williams [États-Unis] ; Anne-Marie Wills [États-Unis]Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.
000877 (2014) Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Katie D. Lewis [Australie] ; James B. Koprich [Canada] ; M Gabriela Reyes [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Jonathan M. Brotchie [Canada]UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.
001142 (2012) Sheridan M. Hoy [Nouvelle-Zélande] ; Gillian M. KeatingRasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
001715 (2011) Jaime Mcdonald [Canada] ; Philippe Corbeil ; Emmanuelle PourcherBalance control improves following replacement of paroxetine with venlafaxine and levodopa in a case of microvascular dementia.
001A92 (2010) André Bonnici [Canada] ; Carola-Ellen Ruiner ; Lyne St-Laurent ; David HornsteinAn interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.
002441 (2007) Vicki Oldfield [États-Unis] ; Gillian M. Keating ; Caroline M. PerryRasagiline: a review of its use in the management of Parkinson's disease.
002805 (2006) Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada]Prevention of levodopa‐induced dyskinesias by a selective NR1A/2B N‐methyl‐D‐aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin
002916 (2006) Jon Doan [Canada] ; Ian Q. Whishaw [Canada] ; Sergio M. Pellis [Canada] ; Oksana Suchowersky [Canada] ; Lesley A. Brown [Canada]Motor deficits in parkinsonian reaching : Dopa-sensitivity influenced by real-world task constraint
002B93 (2004) Anthony E. Lang [Canada] ; Jose A. ObesoChallenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough.
003308 (2001) M. Guttman [Canada] ; D. Stewart [Canada] ; D. Hussey [Canada] ; A. Wilson [Canada] ; S. Houle [Canada] ; S. Kish [Canada]Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD
003310 (2001) Mahyar Etminan [Canada] ; Ali Samii [États-Unis] ; Bahi Takkouche [Espagne] ; Paula A. Rochon [Canada]Increased risk of somnolence with the new dopamine agonists in Patients with Parkinson's disease: A meta-analysis of randomised controlled trials
003372 (2000) L. McauleyEntacapone: adjunctive use in patients with advanced Parkinson's disease.
003561 (2000) Erich Mohr [Canada] ; Tilak Mendis [Canada] ; Kathleen Hildebrand [Canada] ; Peter Paul De Deyn [Belgique]Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial
003802 (1999) P. J. Blanchet [Canada]Rationale for use of dopamine agonists in Parkinson's disease : Review of ergot derivatives
003852 (1998) S M Mirsattari [Canada] ; C. Power ; A. NathParkinsonism with HIV infection.
003962 (1998) D. B. Shoulson [États-Unis]Mortality in DATATOP: A Multicenter trial in early Parkinson's disease
003C69 (1997) R. Kumar [Canada] ; A. E. Lang [Canada]Coexistence of tics and parkinsonism : Evidence for non-dopaminergic mechanisms in tic pathogenesis
003D01 (1996) A M Ghadirian [Canada] ; L. Annable ; M C Bélanger ; G. ChouinardA cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients.
003F15 (1995) H. Shinotoh [Canada] ; B J Snow ; K A Hewitt ; B D Pate ; D. Doudet ; R. Nugent ; D P Perl ; W. Olanow ; D B CalneMRI and PET studies of manganese-intoxicated monkeys.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i -k "Drug Therapy, Combination" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i  \
                -Sk "Drug Therapy, Combination" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Drug Therapy, Combination
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022